接受替妥木单抗治疗患者的再治疗率:一项对119例患者随访1年的多中心研究
这项多中心回顾性研究纳入119例接受完整疗程替妥木单抗治疗的甲状腺眼病(TED)患者,随访1年时再治疗率为24%(29/119),3个中心间无差异(P=0.6)。年龄是再治疗的唯一显著驱动因素,再治疗组比未再治疗组年长7岁(60岁 vs 53岁;P<0.05)。
要点
- 完整疗程替妥木单抗治疗后1年再治疗率为24%(29/119)。
- 年龄是再治疗的唯一显著驱动因素(P<0.05),再治疗组60岁 vs 未再治疗组53岁。
- 基线突眼度(P=0.07)、复视评分(P=0.4)和TED病程(P=0.4)在再治疗与未再治疗组间无显著差异。
核心结论
- 在接受完整疗程替妥木单抗治疗的患者中,再治疗率为24%(29/119)。
- 年龄是再治疗的唯一驱动因素(P<0.05),再治疗患者比未再治疗患者年长7岁(60岁 vs 53岁;P<0.05)。
研究设计与样本
- 多中心回顾性研究,纳入来自美国3个中心的119例接受完整疗程替妥木单抗治疗且初始治疗后1年有可用数据的甲状腺眼病(TED)患者。
- 回顾病历收集年龄、性别、TED诊断后月数、吸烟状态和既往治疗,并在基线、第一疗程结束时及第二疗程基线(接受再治疗者)评估临床活动度评分(CAS)、突眼度和Gorman复视评分。
- 建立逻辑回归模型分析再治疗的驱动因素。
主要发现
- 总体再治疗率为24%(29/119),3个中心间无差异(P=0.6)。
- 单变量分析中,基线突眼度(P=0.07)、复视评分(P=0.4)和TED病程(P=0.4)在再治疗与未再治疗组间无显著差异。
- 再治疗组中82%在初始疗程后显示显著突眼反应(较基线减少≥2 mm),而未再治疗组中68%显示有临床意义的突眼反应(P=0.16)。
- 在再治疗患者中,第一疗程结束与第二疗程基线之间的平均±标准差差值:CAS为2±2,突眼度为2±4 mm,复视评分为1±1。
- 年龄是再治疗的唯一显著驱动因素(P<0.05),再治疗患者比未再治疗患者年长7岁(60岁 vs 53岁;P<0.05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the rate of re-treatment in patients who receive a full course of teprotumumab therapy for thyroid eye disease (TED) and drivers of re-treatment. DESIGN: Multicenter retrospective study. PARTICIPANTS: All patients who received a full course of treatment and had available data at 1 year after initial treatment were included. METHODS: Charts were reviewed for the following information: age, sex, months since diagnosis of TED, smoking status, and prior treatments. Further, the clinical activity score (CAS), proptosis, and the Gorman diplopia score were reviewed at baseline, at the end of the first course, and at baseline for the second course in those who received it. A logistic regression model was created to review the drivers of re-treatment. MAIN OUTCOME MEASURES: Rate of re-treatment and the drivers of re-treatment. RESULTS: One hundred nineteen patients were included from 3 centers across the United States. The overall re-treatment rate was 24% (29/119). No difference was found among the 3 sites (P = 0.6). In univariable analyses, at baseline, no difference was found in proptosis (P = 0.07), diplopia score (P = 0.4), or duration of TED (P = 0.4) between patients who were re-treated and those not re-treated. From the re-treated group, 82% showed a significant proptosis response (≥ 2-mm reduction from baseline) after the initial course, whereas 68% of patients who were not re-treated showed a clinically significant proptosis response (P = 0.16). The mean ± standard deviation difference between the end of the first treatment and at baseline before the second treatment (in those who received it) was 2 ± 2 for CAS, 2 ± 4 mm for proptosis, and 1 ± 1 for diplopia score. Age was the only significant driver of re-treatment (P < 0.05). Re-treated patients were 7 years older than patients who were not re-treated (60 years vs. 53 years; P < 0.05). CONCLUSIONS: In patients receiving a full course of teprotumumab therapy, the rate of re-treatment was 24%. Age was the only driver of re-treatment. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Ugradar S, Parunakian E, Malkhasyan E, et al. The Rate of Re-treatment in Patients Treated with Teprotumumab: A Multicenter Study of 119 Patients with 1 Year of Follow-up. Ophthalmology. 2024. PMID: 39032704. doi:10.1016/j.ophtha.2024.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。